In Vitro and In Vivo Characterization of MEMS Microneedles

Transdermal drug delivery TDD systems have many advantages but are conventionally limited by the low permeability of skin. The idea of using microneedles to painlessly penetrate the topmost impermeable stratum corneum has previously been put forward. In this paper, the fabrication of solid and hollow silicon microneedles with straight side-walls and with the following dimensions: 20–100 μm in diameter and 100–150 μm in length is described. In vitro tests demonstrate that with prior solid microneedle application, transdermal drug transport is significantly increased by 10–20 times, with the degree of enhancement being related to needle diameter. In vivo tests in diabetic animals, however, were unable to demonstrate any delivery of insulin through the hollow microneedles. It is proposed that two factors, microneedle length and tip sharpness, have to be improved for systemic drug delivery to be seen in vivo.

[1]  Albert P. Pisano,et al.  Silicon-processed microneedles , 1999 .

[2]  Mark G. Allen,et al.  Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Allen,et al.  Microfabricated microneedles: a novel approach to transdermal drug delivery. , 1998, Journal of pharmaceutical sciences.

[4]  J. Matriano,et al.  Macroflux® Microprojection Array Patch Technology: A New and Efficient Approach for Intracutaneous Immunization , 2004, Pharmaceutical Research.

[5]  Ian Papautsky,et al.  Micromachined pipette arrays , 2000, IEEE Transactions on Biomedical Engineering.

[6]  R. Bronaugh,et al.  Methods for in vitro percutaneous absorption studies. II. Animal models for human skin. , 1982, Toxicology and applied pharmacology.

[7]  Diane E. Sutter,et al.  Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery , 2002, Nature Medicine.

[8]  B. W. Barry,et al.  Novel mechanisms and devices to enable successful transdermal drug delivery. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  Mark G. Allen,et al.  Lack of pain associated with microfabricated microneedles. , 2001 .

[10]  R M Schulz,et al.  Patient compliance—an overview , 1992, Journal of clinical pharmacy and therapeutics.

[11]  R. Langer,et al.  Transdermal delivery of drugs. , 1988, Annual review of medicine.